Amerika Serikat - Inggris - NLM (National Library of Medicine)

par pharmaceutical inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg - morphine sulfate extended-release capsules, usp are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time (seeclinical pharmacology ). morphine sulfate extended-release capsules, usp are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery), or if the pain is mild or not expected to persist for an extended period of time. morphine sulfate extended-release capsules, usp are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (see american pain society guidelines.) morphine sulfate extended-release capsules are contraindicated in patients with a known hyper

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 200 mg - tablet, modified release - excipient ingredients: magnesium stearate; cetostearyl alcohol; hyetellose; purified talc; macrogol 400; titanium dioxide; hypromellose; brilliant blue fcf; quinoline yellow - ms contin is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms contin is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms contin is not indicated as an as-needed (prn) analgesia.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - capsule, modified release - excipient ingredients: purified talc; purified water; maize starch; gelatin; sucrose; methacrylic acid copolymer; ethylcellulose; hypromellose; macrogol 6000; diethyl phthalate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 100 mg - capsule, modified release - excipient ingredients: sucrose; ethylcellulose; purified water; gelatin; macrogol 6000; maize starch; hypromellose; purified talc; diethyl phthalate; methacrylic acid copolymer; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 50 mg - capsule, modified release - excipient ingredients: hypromellose; methacrylic acid copolymer; gelatin; sucrose; purified talc; maize starch; purified water; ethylcellulose; diethyl phthalate; macrogol 6000; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 20 mg - capsule, modified release - excipient ingredients: methacrylic acid copolymer; macrogol 6000; gelatin; purified water; diethyl phthalate; sucrose; ethylcellulose; maize starch; hypromellose; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain: kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness: kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate -